We licensed-in additional 9 families of patent applications shown below from Kyoto University. Please visit each linked pages to find applicants and inventors. We will provide further information on each page when they are published.
・A method for inducing hepatocyte differentiation
・A novel marker for mature cardiomyocytes
・A prophylactic or therapeutic composition for TDP-43 proteinopathy
・A diagnostic method for motor neuropathy and a method for screening therapeutic agents for the same
・A method for selecting a specific tissue cell type
・A diagnostic method for polycystic kidney disease
・A method for producing pancreatic buds
・A therapeutic agent for Alzheimer disease
・A method for selecting miRNAs for isolating specific cell types
We executed an agreement with St. Marianna University School of Medicine in order to spread the research and application of iPS cell technologies. Under the terms of the agreement, we will make continuous efforts with St. Marianna University School of Medicine for contributing to society through sharing the fruits of iPS cell research.
We executed an agreement with Gifu University in order to spread the research and application of iPS cell technologies. Under the terms of the agreement, we will make continuous efforts with Gifu University for contributing to society through sharing the fruits of iPS cell research.
We executed a non-exclusive license agreement with StemoniX, Inc. which provides a service of iPS cell-derived cells for research use, on the basic and improvement patents which we have been granted a sublicensing right from Kyoto University and from Osaka University respectively.
We just opened a search window on the page of Patent Portfolio for keyword retrieval. It has been made available to search our patent portfolio not only by category, but also by various keywords depending on the descriptions in bibliographic data pages (application No., publication No., inventor, applicant (assignee), title of invention, abstract, etc.), and it would be helpful for you to find available technologies from more than 100 patent families from our Patent Portfolio which is frequently updated. Please try it out and find the one you are looking for.
A business plan of iPS Academia Japan, Inc. for iPS cell technology transfer operations (TLO operations) has been authorized by both the Minister of Education, Culture, Sports, Science and Technology (MEXT) and the Minister of Economy, Trade and Industry (METI) under the TLO Law (Law No. 52, May 6, 1998) in Japan, and then we have become an approved TLO in January 22, 2016.
Our office will be closed for winter holidays from Tuesday 29th December 2015 to Sunday 3rd January 2016.
Please understand that our earliest replay to any inquiries received during the above period will be made on or after Monday 4th January 2016.
We apologize for your inconvenience this may cause you during this period.
We executed a non-exclusive license agreement with Applied StemCell, Inc. which provides iPS cell derived cells and services for iPS cell generation, differentiation and gene modification for research use, on the patents related to iPS cells technology which we have been granted a sublicensing right from Kyoto University.
We presented our exhibition in Japan Pavilion hosted by JETRO at “BIO-Europe2015” in Munich, Germany from November 2nd (Mon.) till November 4th (Fri.), 2015. We very much appreciate many meetings in Munich regarding our possible collaborations.
We executed a license agreement with Cartilize Incorporated which provides iPS cell-derived chondrocyte products for use in therapeutic applications and research purposes, the license allowing exclusive and non-exclusive rights, respectively, on the patents related to chondrocyte induction and those related to iPS cell technology, for all of which we have been granted a sublicensing right from Kyoto University.